Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2017 06:56 ET | Source: Ocera Therapeutics, Inc.

Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy

-- Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right -- -- Hepatic encephalopathy (HE) is a neuropsychiatric syndrome...
March 27, 2017 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera to Present at the 16th Annual Needham Healthcare Conference

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
January 30, 2017 07:00 ET | Source: Ocera Therapeutics, Inc.

Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy

Primary and Secondary Endpoints Showed Trend and Dose-Related Clinical Benefit Although Not Statistically Significant Ammonia Scavenger OCR-002 Demonstrated Statistically Significant Reduction in...
November 09, 2016 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera to Present at the Stifel 2016 Healthcare Conference

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
November 02, 2016 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
October 28, 2016 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that Willard Dere, M.D., Professor of Internal Medicine...
September 21, 2016 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced completion of enrollment in STOP-ALF, a Phase...
September 20, 2016 09:10 ET | Source: Ocera Therapeutics, Inc.

Ocera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
August 03, 2016 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
April 15, 2016 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)

Data establish ammonia-lowering properties of orally-administered OCR-002 in preclinical model of cirrhosisData highlight CNS neurochemical changes occurring in preclinical model of hepatic...

Next Page keyboard_arrow_right